NewcelX定价135万美元股权融资

2026-04-01 20:10

NewcelX (NCEL) announced on Wednesday that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the company’s common shares on March 31, 2026.
Pursuant to the terms of the securities purchase agreements, the company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at $3.025 per share.
The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026.
The company intends to use the net proceeds from the offering, together with its previously announced $25M equity line, to advance NCEL-101, NewcelX’s lead program for Type 1 Diabetes, in collaboration with Eledon Pharmaceuticals, its other development pipeline programs, working capital, and general corporate purposes.
NCEL +7.07% premarket to $2.27.
Source: Press Release

More on NLS Pharmaceutics